Osteonecrosis mandibular asociada con medicamentos. Una revisión bibliográfica.

Abstract

Introduction: Medication-related osteonecrosis of the jaw, formerly known as bisphosphonate-related osteonecrosis of the jaw, is a syndrome first described in 2003. Prescribing some medications, such as bisphosphonates, denosumab, and anti-angiogenic agents, like monoclonal antibodies, have been implicated in the development of Medication-Related Osteonecrosis of the Jaw (MRONJ). Objective: To investigate drugs related to osteonecrosis of the jaw. Materials and methods: Quantitative, cross-sectional descriptive study, through a search in scientific bases, to collect information on medications associated with the production of medication-related osteonecrosis of the jaw. Result: Bisphosphonates have been linked to the production of osteonecrosis of the jaw, as they inhibit osteoclastic activity by altering bone remodeling. Denosumab was introduced as a more effective alternative than bisphosphonates; however, it has also been linked to the production of osteonecrosis of the jaw since this drug induces a sustained decrease in bone turnover. Conclusions: Osteonecrosis of the jaw has been related to some medications, such as Bisphosphonates -especially zoledronic acid-and Denosumab -used to treat osteoporosis and metastatic bone diseases.